Anne Gedebjerg1, Thomas Peter Almdal2, Klara Berencsi3, Jørgen Rungby4, Jens Steen Nielsen5, Daniel R Witte6, Søren Friborg5, Ivan Brandslund7, Allan Vaag8, Henning Beck-Nielsen5, Henrik Toft Sørensen3, Reimar Wernich Thomsen3. 1. Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Danish Diabetes Academy, Odense University Hospital, Odense, Denmark. Electronic address: aged@clin.au.dk. 2. Department of Endocrinology PE, Rigshospitalet, University of Copenhagen, Denmark. 3. Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Endocrinology IC, Bispebjerg University Hospital, Copenhagen, Denmark. 5. Diabetes Research Centre, Department of Endocrinology, Odense University Hospital, Odense, Denmark. 6. Danish Diabetes Academy, Odense University Hospital, Odense, Denmark; Department of Public Health, Aarhus University, Aarhus, Denmark. 7. Department of Biochemistry, Lillebaelt Hospital, Vejle, Denmark. 8. AstraZenaca, Mölndal, Sweden.
Abstract
AIMS: To examine the prevalence of micro- and macrovascular complications and their associated clinical characteristics at time of type 2 diabetes (T2D) diagnosis. METHODS: We examined the prevalence of complications and associated clinical characteristics among 6958 newly diagnosed T2D patients enrolled in the prospective Danish Center for Strategic Research in T2D cohort during 2010-2016. We calculated age- and gender-adjusted prevalence ratios (aPRs) of complications using log-binomial and Poisson regression. RESULTS: In total, 35% (n=2456) T2D patients had diabetic complications around diagnosis; 12% (n=828) had microvascular complications, 17% (n=1186) macrovascular complications, and 6% (n=442) had both. HbA1c levels of ≥7% were associated with microvascular complications [HbA1c 7%-8%; aPR: 1.35, 95% confidence interval (CI): 1.12-1.62] but not macrovascular complications [aPR: 0.91, 95% CI: 0.76-1.08]. High C-peptide≥800pmol/L was associated with macrovascular [aPR 1.34, 95% CI: 1.00-1.80] but not microvascular [aPR 0.97, 95% CI: 0.71-1.33] complications. Macrovascular complications were associated with male sex, age>50years, obesity, hypertriglyceridemia, low HDL cholesterol, smoking, elevated CRP levels, and anti-hypertensive therapy. Microvascular complications were associated with high blood pressure, hypertriglyceridemia, and absence of lipid-lowering therapy. CONCLUSIONS: One-third of patients with T2D had diabetes complications around time of diagnosis. Our findings suggest different pathophysiological mechanisms behind micro- and macrovascular complications.
AIMS: To examine the prevalence of micro- and macrovascular complications and their associated clinical characteristics at time of type 2 diabetes (T2D) diagnosis. METHODS: We examined the prevalence of complications and associated clinical characteristics among 6958 newly diagnosed T2D patients enrolled in the prospective Danish Center for Strategic Research in T2D cohort during 2010-2016. We calculated age- and gender-adjusted prevalence ratios (aPRs) of complications using log-binomial and Poisson regression. RESULTS: In total, 35% (n=2456) T2D patients had diabetic complications around diagnosis; 12% (n=828) had microvascular complications, 17% (n=1186) macrovascular complications, and 6% (n=442) had both. HbA1c levels of ≥7% were associated with microvascular complications [HbA1c 7%-8%; aPR: 1.35, 95% confidence interval (CI): 1.12-1.62] but not macrovascular complications [aPR: 0.91, 95% CI: 0.76-1.08]. High C-peptide≥800pmol/L was associated with macrovascular [aPR 1.34, 95% CI: 1.00-1.80] but not microvascular [aPR 0.97, 95% CI: 0.71-1.33] complications. Macrovascular complications were associated with male sex, age>50years, obesity, hypertriglyceridemia, low HDL cholesterol, smoking, elevated CRP levels, and anti-hypertensive therapy. Microvascular complications were associated with high blood pressure, hypertriglyceridemia, and absence of lipid-lowering therapy. CONCLUSIONS: One-third of patients with T2D had diabetes complications around time of diagnosis. Our findings suggest different pathophysiological mechanisms behind micro- and macrovascular complications.
Authors: Nasrin S Saiyed; Umar Yagoub; Bandar Al Qahtani; Attiya Mohammed Al Zahrani; Ibrahim Al Hariri; Meerab Javed Syed; Mohammed Elmujtaba Elmardi; Muhammad Abdullah Tufail; Marwan Manajreh Journal: J Multidiscip Healthc Date: 2022-07-27
Authors: José Gerardo González-González; Ricardo Cesar Solis; Alejandro Díaz González-Colmenero; Karina Raygoza-Cortez; Pablo J Moreno-Peña; Alicia L Sánchez; Rozalina G McCoy; Naykky Singh Ospina; Spyridoula Maraka; Juan P Brito; René Rodriguez-Gutierrez Journal: Diabetes Res Clin Pract Date: 2022-03-02 Impact factor: 8.180